SGLT2 inhibitors and hemoglobin rise: does it matter in clinical practice?

A large meta-analysis led by nephrologist Michel Eisenga found that SGLT2 inhibitors, used in type 2 diabetes, heart failure and chronic kidney disease, consistently raise hemoglobin and hematocrit levels. The authors also assessed iron metabolism markers. Importantly, this is an effect on laboratory values, not proven clinical benefit. What shall we discuss: — Have you noticed higher hemoglobin or hematocrit in patients taking empagliflozin or dapagliflozin, and how do you factor it in when interpreting labs, for example in anemia of CKD? — How would you explain the effect: hemoconcentration from diuresis, influence on erythropoiesis and iron metabolism, or a combination? Which seems most important to you? — Should this be seen as part of the benefit of these drugs in heart failure and CKD, or is it so far just a marker without proven clinical significance? For USMLE and practice, it helps to link the proximal tubule action of SGLT2 inhibitors, their indications in heart failure and CKD, and their adverse effects with how lab values change on treatment. Full article: drasiiavinograd.com/blog/sglt2-inhibitors-and-hemoglobin-usmle-meta-an Source: Medical Xpress medicalxpress.com/news/2026-10-large-meta-analysis-sglt2-inhibitors.ht